OMEROS CORP Senior Notes, Current
OMEROS CORP (OMER) had Senior Notes, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current › Notes and Loans Payable, Current
us-gaap:SeniorNotesCurrent · last filed 2026-08-12
- 2026-06-30: Senior Notes, Current $0.00.
- 2026-03-31: Senior Notes, Current $0.00.
- 2025-12-31: Senior Notes, Current $17.06M.
- 2025-09-30: Senior Notes, Current $17.04M.
| Period end | Senior Notes, Current | Senior Notes, Current as first filed |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $17.06M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $17.04M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $17.02M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $26.93M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-31 | $21.00M 10-K · filed 2025-03-31 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | |
| 2023-09-30 | $94.91M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $94.73M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $94.55M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $94.38M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |